Announced details
Cancer immunotherapy; multiple solid tumors, including gastric and pancreatic cancer
Joint research partner. No capital or personnel relationship is disclosed.
An Italian public research institution. Established in Naples in 1983, it is a nonprofit research institution funded entirely by public capital. It conducts research and diagnostics for genetic diseases and works in molecular biology and advanced biotechnology related to human health.
Naples, Italy (CEINGE's place of establishment)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Frontiers in Immunology (publication venue)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Tribody® 53L10, Tribody® |
| Counterparty | CEINGE-Biotecnologie Avanzate Franco Salvatore（CEINGE） |
| Counterparty overview | An Italian public research institution. Established in Naples in 1983, it is a nonprofit research institution funded entirely by public capital. It conducts research and diagnostics for genetic diseases and works in molecular biology and advanced biotechnology related to human health. |
| Relationship with the Company | Joint research partner. No capital or personnel relationship is disclosed. |
| Applicable area | Cancer immunotherapy; multiple solid tumors, including gastric and pancreatic cancer |
| Location | Naples, Italy (CEINGE's place of establishment) |
| Source | Frontiers in Immunology (publication venue) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the results of joint research by the Company and CEINGE were published in the international academic journal Frontiers in Immunology.